Protein tyrosine phosphatases (PTPs) are key mediators that link physiological cues with reversible changes in protein structure and function; nevertheless, significant details concerning their regulation in vivo remain unknown. We demonstrate that PTP associates with microtubules in vivo and is inhibited by them in a noncompetitive manner. Microtubule-associated proteins, which interact strongly with microtubules in vivo, significantly increase binding of PTP to tubulin in vitro and further reduce phosphatase activity. Conversely, disruption of microtubule structures in cells reduces their association with PTP, alters the subcellular localization of the phosphatase, and increases its specific activity. Activation of the epidermal growth factor receptor (EGFR) increases the PTP-microtubule association in a manner dependent upon EGFR-induced phosphorylation of PTP at Y638 and upon microtubule integrity. These events are transient and occur with rapid kinetics similar to EGFR autophosphorylation, suggesting that activation of the EGFR transiently down-regulates PTP activity near the receptor by promoting the PTP-microtubule association. Tubulin also inhibits the tyrosine phosphatase PTP1B but not receptor-type PTP or the unrelated alkaline phosphatase. The data suggest that reversible association with microtubules is a novel, physiologically regulated mechanism for regulation of tyrosine phosphatase activity in cells.
Reversible phosphorylation of tyrosine residues in proteins is a major regulator of protein structure and function. Tyrosine phosphorylation of proteins is regulated in part by the activity of members of the protein tyrosine phosphatase (PTP) superfamily, which currently includes over 100 genes in higher organisms. Of these, 38 genes encode "classical" tyrosine phosphatases (PTPs), which are strictly specific for phosphotyrosine. Products of this gene family all contain one or two copies of the PTP domain and are either receptor-type integral membrane proteins or non-receptor-type proteins (1, 3) .
The numbers of known tyrosine kinases and tyrosine phosphatases are similar and small compared to the numbers and complexities of their potential substrates (1) . The apparent contradiction between this and the high degree of specificity that exists in signaling processes in vivo has made understanding the mechanisms by which PTP activity is regulated of paramount importance. PTP genes often produce several distinct protein products by alternative splicing or use of alternative promoters (3) . At the protein level, PTP activity can be inhibited by dimerization (e.g., see references 22, 23, and 43) or by reversible oxidation of the key cysteine residue in the PTP catalytic domain (9, 44) . Proteolysis and phosphorylation, which can affect subcellular localization, conformation, or the ability to bind other proteins can also activate or inhibit PTPs (e.g., see references 6, 13, 17, 48, and 49) . Regulation of PTP activity by binding of extracellular ligands to receptor-type PTPs (RPTPs), which inhibits PTP activity and appears to be less common than among tyrosine kinases, has also been described (e.g., see reference 14) . Despite these insights, major gaps still exist in our understanding of how PTP activity is regulated in a reversible manner and within the short time periods typical of signal transduction events.
The two major forms of PTPε known today are RPTPε and the non-receptor form (cyt-PTPε), which differ only at their N termini and which are products of distinct promoters of the single Ptpre gene (10, 11, 31, 36) . Other protein forms of PTPε are p67 PTPε and p65 PTPε, whose production is regulated at the levels of transcription and posttranslational processing, respectively (17, 18) . RPTPε dephosphorylates c-Src and the related kinases c-Yes and c-Fyn at their C-terminal inhibitory tyrosine, thereby activating the kinases and assisting mammary tumor cells induced in vivo by Neu to maintain their transformed phenotype (16, 19) . RPTPε has also been suggested to downregulate insulin receptor signaling (2, 25, 28, 30) . cyt-PTPε is important for proper adhesion of osteoclasts to bone (7) and dephosphorylates and downregulates delayed-rectifier voltage-gated potassium channels in Schwann cells, thereby countering their activation by c-Src and c-Fyn. This effect correlates in vivo with delayed myelination of sciatic nerve axons in young PTPε-deficient mice (33, 40, 41) and with delayed optic nerve myelination in mice expressing a "substrate-trapping" mutant of RPTPε (29) . cyt-PTPε can also downregulate signaling mediated by the mitogen-activated protein kinase (42, 45) and JAK-STAT (37-39) pathways and is required for proper functioning of mouse macrophages (35) .
In order to better understand at the molecular level the physiological roles and regulation of PTPε activity in vivo, we searched for novel interactors with this phosphatase. We report here that PTPε interacts in vivo with microtubules in a reversible manner. Binding is stabilized by microtubule-associated proteins (MAPs) and is regulated by physiological stim-uli, such as specific phosphorylation of PTPε following activation of the epidermal growth factor receptor (EGFR). Binding to tubulin inhibits PTPε catalytic activity, suggesting that physiologically relevant signaling events may down-regulate PTPε activity by promoting its transient association with microtubules. Our data indicate that tubulin also inhibits PTP1B but does not inhibit RPTP, suggesting that while association with tubulin is not universal among PTPs, it is not limited to PTPε alone.
g and then at 100 ϫ 10 3 g at 4°C to remove polymerized microtubules. In vitro polymerization of microtubules from the supernatant was performed in G-MESϩϩ buffer (MESϩϩ buffer supplemented with 4 M glycerol, 1 mM GTP, 0.4 mM DTT, 5 M Taxol, and protease inhibitors) for 45 min at 37°C. Following centrifugation at 100 ϫ 10 3 g at 37°C, the pellet containing polymerized microtubules was washed three times in MESϩϩ buffer and was dissolved in 200 l of buffer A (50 mM Tris-Cl [pH 7.5], 150 mM NaCl, 1% Nonidet P-40). The experiment shown in Fig. 1F was carried out in a similar manner, except that purified cyt-PTPε was added prior to the polymerization step.
Immunoprecipitation and protein blotting. Immunoprecipitation and elution of FLAG-tagged PTPε expressed in 293 cells were carried out as described previously (41) . The purity and amounts of eluted material were determined by gel electrophoresis and silver staining. In some studies, endogenous tubulin or PTP1B was precipitated from 1-mg cell lysates prepared in buffer A using the relevant antibodies and protein A/G Sepharose beads (Santa Cruz). Tyrosinephosphorylated Kv2.1 for use as a substrate of PTPε was purified from 293 cells cotransfected with FLAG-tagged Kv2.1 and activated (Y527F) Src by anti-FLAG immunoprecipitation and elution with FLAG peptide as described previously (41) . Sodium dodecyl sulfate (SDS) gel electrophoresis, blotting, and antibody hybridization were done as described previously (18) .
Phosphatase and kinase activity assays. Phosphatase activity was assayed in 96-well plates. Each well typically contained 0.1 g of PTPε in 200 l of activity assay buffer (50 mM MES, 0.5 mg/ml bovine serum albumin, 0.5 mM DTT, and 10 mM para-nitrophenylphosphate [PNPP], pH 7.0). Under these conditions PTPε activity is linear with time and amount of enzyme. Increasing amounts of purified bovine tubulin, bovine serum albumin (BSA; fraction V [MP Biomedicals, Solon, OH]) or actin (Sigma) were added, and activity was measured by monitoring the increase in absorption at 405 nm at room temperature for 1 h. The K m and V max for PTPε were determined by Lineweaver-Burk analysis by measuring initial PTPε activity in the presence of increasing concentrations of PNPP (0.6 to 15.0 mM) for 5 to 10 min, with or without added tubulin. In some studies, the phosphatase activity of 0.3 g of calf intestinal alkaline phosphatase (CIP; New England Biolabs, Beverly, MA), 0.6 g of the cytosolic domain of RPTP (Jena Biosciences GmbH, Jena, Germany), or 0.3 g of endogenous PTP1B precipitated from 293 cells was measured similarly. In other studies, 25 ng of eluted phospho-Kv2.1 was incubated either alone or with 30 ng of purified cyt-PTPε and with 25 to 50 g purified bovine brain tubulin, actin, or BSA in PTP activity buffer at 32°C for 2 h. The reaction was terminated by addition of SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer and boiling. Phosphorylation of Kv2.1 was analyzed by SDS-PAGE and protein blotting with anti-pTyr antibodies. Src activity assay was performed using enolase according to reference 16 .
Interaction between tubulin and PTP. Eluted cyt-PTPε (0.1 g) was incubated with 20 g purified bovine tubulin, either with or without 15.5 g eluted bovine MAPs, for 1 h at room temperature. PTPε was immunoprecipitated with anti-FLAG antibodies, and associated tubulin was detected by protein blotting. To examine the interaction in cells following EGFR stimulation, endogenous or exogenous EGFR was stimulated in 293 cells with 100 ng/ml of EGF (Sigma) or vehicle (PBS). Cells were lysed in buffer A supplemented with 0.5 mM sodium vanadate at various time points; FLAG-tagged cyt-PTPε was immunoprecipitated and examined by protein blotting. Detection of cyt-PTPε phosphorylation following EGFR stimulation was done in a similar manner using buffer A containing 0.5 mM sodium pervanadate.
RESULTS

PTP binds tubulin in vivo.
In order to identify proteins that interact with PTPε in cells, we expressed the nonreceptor form of the phosphatase, cyt-PTPε, in 293 cells and examined proteins that coprecipitated with it. In this study, we utilized D245A cyt-PTPε, a "substrate-trapping" mutant of PTPε that is virtually inactive but retains the ability to bind substrates and interacting molecules in a cellular context (12) . SDS-PAGE analysis of D245A cyt-PTPε immunoprecipitates revealed a coprecipitating protein with a mass of approximately 55 kDa that was subsequently identified by mass spectrometry as ␣-tubulin (not shown). Further immunoprecipitation experiments confirmed that cyt-PTPε as well as RPTPε bound ␣-tubulin (Fig. 1A) . Both WT and D-to-A trapping mutants of cyt-PTPε and RPTPε bound ␣-tubulin similarly (Fig. 1A) ; this result, therefore, does not shed light on whether or not tubulin is a substrate of PTPε, although it does indicate that a complex that contains both molecules exists. Binding was specific since a nonrelated protein, DAP4, did not bind ␣-tubulin and since actin, a second cytoskeletal protein of high abundance, did not coprecipitate with PTPε ( Fig. 1A and B) . The association between PTPε and ␣-tubulin was observed also in HeLa and in A431 cells, as well as when the experiment was performed in reverse by precipitating ␣-tubulin (see Fig. 3B ) (data not shown). Similar results were obtained also when binding to ␤-tubulin was examined (not shown); subsequent experiments were therefore performed with antibodies against ␣-tubulin alone. In separate experiments, comparison of the fraction of FLAG-tagged cyt-PTPε molecules that coprecipitated with a given fraction of precipitated tubulin molecules in 293 cells indicated that 10 to 15% of cyt-PTPε molecules and 0.3 to 0.4% of tubulin molecules participate in the PTPε-tubulin interactions. The last result agrees with the expression level of tubulin in these cells, which is significantly higher than that of cyt-PTPε.
Similar results were obtained when binding between endogenous PTPε and ␣-tubulin was examined. Accordingly, endogenous cyt-PTPε coprecipitated with ␣-tubulin from Jurkat T cells (Fig. 1C) . In separate experiments, mouse brain lysate, which had been cleared of polymerized microtubules by centrifugation (Fig. 1D, lanes 1 and 2) , was incubated at 37°C in the presence of GTP and glycerol to promote assembly of nonpolymerized tubulin dimers into microtubules. Following their collection by centrifugation, examination of the newly assembled microtubules (Fig. 1D , lanes 3 and 4) revealed that significant amounts of endogenous RPTPε had coassembled and copurified with the precipitated microtubules. Similar results were obtained when binding of endogenous RPTPε to microtubules was examined in mammary tumor cells induced in vivo in mice by expression of an activated Neu transgene (Fig. 1E ). Tau, a well-known MAP, was also enriched significantly in the precipitated microtubule fraction (Fig. 1D ). Similar binding was observed when exogenous FLAG-tagged cyt-PTPε that had been purified from overexpressing cells was added to depolymerized tubulin obtained from mice genetically lacking PTPε prior to polymerization in vitro (Fig. 1F) .
The interaction between PTPε and tubulin was reconstituted in vitro using purified cyt-PTPε and tubulin. These studies used tubulin from bovine brain that had undergone three cycles of assembly/disassembly and was stripped of tightly associated MAPs by phosphocellulose column chromatography. Tubulin was first incubated with cyt-PTPε, cyt-PTPε was then immunoprecipitated via its FLAG tag, and the presence of associated ␣-tubulin was examined by protein blotting. As seen in Fig. 1G , PTPε-bound ␣-tubulin was readily detected under these conditions. Interestingly, binding was strengthened significantly when MAPs, which were previously removed from tubulin during its purification, were added to the incubation mixture (Fig. 1G ). Neither ␣-tubulin nor PTPε was detected in the MAP fraction. We conclude, therefore, that the tubulin-cyt-PTPε interaction is stabilized significantly by one or more components of the MAP fraction, which are physiological interactors of microtubules. In all, these results indicate that stable interactions exist between microtubules and the major forms of PTPε, RPTPε and cyt-PTPε.
cyt-PTP colocalizes with microtubules in cells. The interaction between cyt-PTPε and microtubules was visualized in HeLa cells expressing fluorescently tagged cyt-PTPε and ␣-tubulin. Cells were fixed and permeabilized in cold methanol, which removes most soluble cytosolic molecules including nonbound cyt-PTPε. cyt-PTPε and tubulin colocalized throughout the cytosol in long fibrous structures ( Fig. 2A to C and G to I); cyt-PTPε was detected also in the nucleus, in agreement with previous studies (24) . Treatment of cells with nocodazole disrupted the cellular microtubule array and led to a diffuse, punctate cytosolic localization pattern for tubulin (Fig. 2E) . Importantly, nocodazole treatment disrupted localization of cyt-PTPε ( Fig. 2D and F) , confirming that cyt-PTPε was associated with microtubules prior to nocodazole treatment. The qualitative nature of this experiment precluded quantitative conclusions about the effect of nocodazole on the PTPε-microtubule interaction. In order to address the last point, we expressed cyt-PTPε in 293 cells and disrupted their microtubules with nocodazole or colchicine. Coprecipitation of cyt-PTPε with ␣-tubulin was reduced in treated cells (Fig. 2J) , indicating that disruption of the microtubule array reduces binding of PTPε. Stabilization of microtubules with taxol enhanced this interaction in some experiments (e.g., The N terminus and the D2 PTP domains of cyt-PTP play major roles in binding tubulin. Throughout the above studies, full-length cyt-PTPε consistently bound more ␣-tubulin than p67 PTPε, a naturally occurring form of cyt-PTPε that lacks the 27 N-terminal residues (18) (Fig. 3A and B) . This observation suggested that the N-terminal domain of cyt-PTPε mediates at least part of the ability of this PTP to bind ␣-tubulin. Further studies indicated that deletion of the first eight amino acids of cyt-PTPε did not affect association between cyt-PTPε and ␣-tubulin (Fig. 3B) . In contrast, deletion of residues 1 to 22 or 11 to 27 or deletion of a larger portion of cyt-PTPε beginning at residue 13 and extending to the C terminus of the first PTP domain (construct D2ϩ12) reduced binding to levels observed with p67 PTPε (Fig. 3B and C) . These results suggest that at a minimum, residues between positions 13 and 22 participate in binding of cyt-PTPε to ␣-tubulin. These residues do not contain sequence motifs known to regulate binding to tubulin heterodimers or to microtubules; they do, however, include several charged residues and a potential phosphorylation site that may regulate binding indirectly.
In order to examine the role of the second, inactive (D2) PTP domain of cyt-PTPε in binding ␣-tubulin, we examined the tubulin-binding abilities of cyt-PTPε lacking this domain (Fig. 3A) . Removal of the D2 PTP domain greatly reduced binding of cyt-PTPε to ␣-tubulin (Fig. 3C, left panel) , attesting to its central role in mediating this interaction. Binding of Y638F cyt-PTPε, which lacks a prominent phosphorylation site at the C terminus of D2, was reduced significantly (Fig. 3D ). This indicates that the presence of Y638 plays an important, but not exclusive, role in mediating the contribution of D2 to the PTPε-tubulin interaction. Participation of several domains of PTP molecules, including the D2 domain, in intermolecular associations of PTPs has been noted before (e.g., see reference 22) .
Tubulin inhibits PTP activity in a specific manner. In order to examine in vitro the consequences of the interaction between tubulin and cyt-PTPε we determined the relative amounts of both proteins in cells and tissues. For this purpose, protein lysates from several sources were analyzed by protein blotting. Membranes were probed with antibodies against ␣-tubulin or PTPε; the absolute amount of either protein in each sample was estimated by comparison to the signal generated by known amounts of purified tubulin or cyt-PTPε that were analyzed in parallel. As expected, a marked excess of ␣-tubulin was detected in all samples, with the ␣-tubulin/PTPε molar ratio (calculated per ␣-tubulin monomer) ranging from approximately 10:1 in Neu-induced mouse mammary tumor cells particularly rich in RPTPε to 1,315:1 in murine embryo fibroblasts (Fig. 4A) .
Interactions between microtubules and PTPε may affect either molecule or other molecules that interact with them. In order to begin addressing this issue, we examined the catalytic activity of cyt-PTPε in vitro in the presence of purified tubulin. Addition of tubulin in excesses of 100-, 500-, and 1,000-fold versus cyt-PTPε reduced PTPε activity to 79.9%, 42.2%, and 25.4% of activity in the absence of tubulin, respectively ( ; n ϭ 3; P ϭ 0.0128 by Student's t test). The ability of tubulin to inhibit PTPε in vivo is likely to be stronger than measured here given the more significant amounts of microtubules and the presence of MAPs in cells, both of which increase the PTPε-tubulin interaction. These results also suggest that tubulin is not a substrate of cyt-PTPε and does not inhibit the phosphatase by competing against other substrates, in agreement with significant involvement of regions outside the D1 PTP domain in binding tubulin (Fig. 3) . Further studies indicated that the effect of tubulin was specific, since addition of 100-, 500-, or 1,000-fold excesses of actin or of BSA did not inhibit cyt-PTPε (Fig. 4C) . Addition of actin actually increased cyt-PTPε activity somewhat, possibly due to increased effective concentrations of both cyt-PTPε and PNPP due to molecular exclusion effects of the added actin. Additional studies indicated that a different tyrosine phosphatase, PTP1B, is also inhibited in vitro by tubulin, but that a third PTP, the receptor-type RPTP, and alkaline phosphatase, which is not a PTP, are not inhibited (Fig. 4C ). RPTPm contains a C-terminal tyrosine residue embedded in a sequence distinct from that of PTPε; it does not contain a sequence similar to the N-terminal sequence of cyt-PTPe. Binding of microtubules is therefore not unique to PTPε within the PTP family and needs to be examined for individual PTPs. We next examined whether modulation of the interaction between cyt-PTPε and microtubules affects phosphatase activity. Treatment of cells with nocodazole reduced binding of cyt-PTPε to tubulin (Fig. 2J) , an effect that would be expected to increase cyt-PTPε activity. In order to test this, we treated 293 cells expressing cyt-PTPε with nocodazole, immunoprecipitated the phosphatase, and assayed its activity. cyt-PTPε isolated from cells treated with nocodazole was 20.3% more active than the enzyme from untreated cells (Fig. 5A ). Since only a fraction of cyt-PTPε molecules bind tubulin, the data in Fig. 5A , which were obtained using total cellular cyt-PTPε, most likely underestimate the effect of nocodazole on cyt-PTPε activity in cells. Importantly, this experiment demonstrates that association with microtubules can affect the activity of cyt-PTPε isolated from cells and that its effect is not limited to experiments in which purified components are combined in vitro.
Addition of MAPs increased binding of purified cyt-PTPε and tubulin in vitro (Fig. 1G) , suggesting that MAPs may further reduce cyt-PTPε activity by stabilizing the PTPε-tubulin interaction. In agreement, addition of 25 g purified tubulin to 0.1 g purified cyt-PTPε reduced cyt-PTPε activity to 85.1% of cyt-PTPε activity in the absence of tubulin, while the presence of MAPs decreased activity further to 72.3% (Fig. 5B) . In the absence of tubulin, MAPs did not inhibit cyt-PTPε activity (not shown), consistent with MAPs reducing cyt-PTPε activity by promoting its interaction with tubulin.
We next examined the effect of purified tubulin on the in vitro activity of cyt-PTPε towards a physiological substratethe voltage-gated potassium channel Kv2.1. Activation of Kv2.1 by depolarization of the cell membrane can be increased by phosphorylation at Y124 by c-Src or c-Fyn; cyt-PTPε counters this effect by dephosphorylating Kv2.1 mainly at Y124 (33, 40, 41) . Kv2.1 was coexpressed with activated (Y527F) Src in 293 cells, and phosphorylated Kv2.1 (pKv2.1) was immunoprecipitated and purified. Equal amounts of pKv2.1 were incubated with cyt-PTPε in the presence or absence of a 250-or 500-fold molar excess of purified tubulin, actin, or BSA. The remaining pKv2.1 was detected by blotting the purified Kv2.1 with antiphosphotyrosine antibodies. In agreement with the data obtained using PNPP (Fig. 4) , the presence of tubulin, but not of actin or BSA, inhibited dephosphorylation of pKv2.1 by cyt-PTPε (Fig. 5C) . Finally, cyt-PTPε activates Src (16), suggesting that disrupting the PTPε-microtubule interaction may further increase Src activity in cells. Treatment of 293 cells expressing WT Src with nocodazole reduced Src activity to 55.2%Ϯ13.3% of Src activity in nontreated cells (mean Ϯ SE; P ϭ 0.0266 by paired t test; n ϭ 5 to 6). Expression of cyt-PTPε increased Src activity slightly to 110.2% Ϯ 18.6%, while treatment of cyt-PTPε-expressing cells with nocodazole increased Src activity further to 160.3% Ϯ 31.7% (mean Ϯ SE; P ϭ 0.0318 by paired t test; n ϭ 6 [ Fig. 5D]) . Increased Src activity in the presence of PTPε in cells following microtubule disruption is consistent with microtubules inhibiting cyt-PTPε in vivo, although further studies are required to determine whether this is caused exclusively by breakdown of the PTPε-microtubule interaction. EGFR-mediated phosphorylation at Y638 drives cyt-PTP to bind tubulin in vivo. Previous studies have shown that activation of the EGFR results in phosphorylation of cyt-PTPε within minutes in a temporal pattern that follows closely autophosphorylation of the EGFR itself. This phenomenon occurs when either exogenous (41) or endogenous (Fig. 6A) EGFR is examined. Interestingly, EGFR signaling also resulted in increased association between cyt-PTPε and ␣-tubulin that followed a very similar time course (Fig. 6B) . Basal association between cyt-PTPε and tubulin was detected in the cells studied (not visible in the exposure shown in Fig. 6B ). Association between tubulin and cyt-PTPε increased significantly as early as 1 min following addition of EGF to the cells; the association peaked at 2.5 and 5 min and receded afterwards. Disruption of microtubules with colchicine reduced basal association between cyt-PTPε and tubulin and prevented its increase following stimulation with EGF (Fig. 6C) .
The temporal correlation between EGFR activation, cyt-PTPε phosphorylation, and association between ␣-tubulin and cyt-PTPε suggests that phosphorylation of cyt-PTPε may regulate its ability to bind tubulin. A prime candidate site for EGFR-mediated phosphorylation of cyt-PTPε is its C-terminal Y638, whose presence supports the PTPε-tubulin interaction (Fig. 3D) . Y638 is analogous to Y695 of RPTPε and to Y789 of the related RPTP␣, whose phosphorylation is crucial for PTPmediated activation of c-Src (4, 49) . In agreement, Y638F cyt-PTPε was not phosphorylated even following activation of exogenous EGFR, which phosphorylates WT cyt-PTPε and promotes its association with microtubules more strongly than the endogenous EGFR (Fig. 7A) (data not shown) . This result indicates that EGFR-mediated phosphorylation of cyt-PTPε is highly specific and affects this single tyrosine from among the 22 tyrosine residues present in this phosphatase.
In order to determine whether EGFR-mediated phosphorylation of cyt-PTPε at Y638 is important for cyt-PTPε-tubulin binding, we examined this association in 293 cells following stimulation of their endogenous EGFR. As in previous experiments, the association between WT cyt-PTPε and ␣-tubulin increased transiently during the first few minutes following EGFR stimulation. In contrast, no increase in binding of ␣-tubulin was observed in cells expressing Y638F cyt-PTPε (Fig.  7B) . cyt-PTPε autodephosphorylates strongly (4), a finding that precluded isolation of cyt-PTPε and measuring its activity while still phosphorylated and associated with microtubules immediately following EGFR activation. Nevertheless, results presented in this study indicate that cyt-PTPε is inhibited by associating with microtubules in cells and that this association is influenced by transient phosphorylation of cyt-PTPε at Y638 that occurs in vivo following physiological activation of the EGFR.
DISCUSSION
In this study, we show that microtubules are physiological interactors of PTPε and that this association inhibits activity of PTPε. The association between microtubules and the two major forms of PTPε, RPTPε and cyt-PTPε, can be detected biochemically when the endogenous proteins are examined as well as when PTPε is expressed in a variety of cells. Furthermore, tubulin and cyt-PTPε colocalize in microtubule structures, and the organizations of both proteins are affected strongly and similarly when microtubules are disrupted. Importantly, actin, another major cytoskeletal protein, does not associate with PTPε under the same conditions, attesting to the specificity of this interaction.
The tubulin-PTPε interaction can also be recapitulated in vitro using purified proteins. A striking finding here is that the interaction is strengthened significantly in the presence of MAPs (Fig. 1G) . The finding that a third protein component that is known to bind microtubules physiologically stabilizes the PTPε-tubulin interaction further supports its physiological context. This finding also suggests that the interaction between PTPε and microtubules may be indirect, accounting in part for how PTPε and PTP1B, which are structurally distinct, can both be influenced by microtubules. Finally, the requirement for MAPs and absence of PTPε from the MAP fraction itself indicate that the phosphatase is not among the proteins that interact most tightly with microtubules, further suggesting that this interaction may be subject to dynamic regulation by physiological processes.
Analysis of the structural requirements of this interaction sheds light on its regulation and further supports its physiological relevance. The role of the D2 PTP domain is crucial, since deleting it significantly reduces the interaction. Phosphorylation of Y638 in the D2 domain of cyt-PTPε (Y695 in RPTPε) plays a significant, but not exclusive, role in supporting the interactions mediated by D2. The role of the short Nterminal region of cyt-PTPε is also striking, since removal of residues 13 to 22 of this domain decreases binding by about 50%. Several tubulin-binding sequence motifs have been described to date, such as the imperfect 18-residue repeats of MAP2 and Tau (21, 27) , multiple copies of the short KKEE/ I/V motif found in MAP1B (32) , or the PX 6 EX 4 L motif found in dynein heavy chain, kinesin, and related molecules (46) . None of these motifs are present in cyt-PTPε, suggesting that cyt-PTPε binds tubulin via an uncharacterized domain or that binding is indirect. As indicated above, the latter possibility is consistent with enhancement of the cyt-PTPε-tubulin interaction by MAPs. The first 27 residues of cyt-PTPε contain 9 positively charged residues and 6 serine/threonine potential phosphorylation sites; of these, 4 charged residues and 1 serine are located between positions 13 and 22. Further study is Binding of PTPε to tubulin may affect the phosphatase, microtubules, or other proteins that associate with microtubules. Limited available information indicates that tubulin is phosphorylated in B lymphocytes by the tyrosine kinase Syk and following stimulation of Jurkat T cells with alpha interferon (47) . In other studies, c-Fes phosphorylated tubulin and promoted tubulin polymerization in vitro (26) . The tyrosine phosphatase PTP-BL localizes to centrosomes during interphase and metaphase and to the spindle midzone during anaphase, and elevated PTP-BL expression leads to defects in cytokinesis (20) . CDC14B, a dual-specificity phosphatase, binds and stabilizes microtubules in vitro and in interphase cells (8) . We detected basal phosphorylation of tubulin, although this was not affected by expression of PTPε (not shown).
In this study, we focused on the effect of binding on PTPε activity, showing that presence of tubulin inhibits cyt-PTPε activity in vitro when both proteins are present in ratios in the range found in cells and tissues. Importantly, tubulin inhibited PTPε activity also towards Kv2.1 and towards Src, both of which are physiological substrates of the phosphatase. The finding that tubulin inhibits PTPε activity while similar amounts of actin or BSA do not do so argues strongly that tubulin has a unique effect on the phosphatase. Similarly, the ability of tubulin to inhibit the tyrosine phosphatase PTP1B but not RPTPm or the unrelated alkaline phosphatase suggests that the effect of tubulin is not common to all types of phosphatases and should be examined on a case-by-case basis within the PTP family. Of note, PTP1B does not contain the N-terminal and D2 domains of cyt-PTPε, which play important roles in binding tubulin. This suggests that the mechanisms by which both PTPs interact with tubulin are distinct.
In support of the above results, treatments that affect binding of cyt-PTPε to microtubules cause the expected changes in cyt-PTPε activity. Accordingly, addition of MAPs purified from bovine brain, which increase binding of cyt-PTPε to tubulin, significantly increased the inhibitory effect of tubulin on activity of purified cyt-PTPε (Fig. 5B) . These results indicate that interactions with other proteins may modify further the effect of tubulin on PTPε activity in vivo. In other experiments, disruption of the cellular microtubule network by nocodazole treatment increased activity of cyt-PTPε purified from these cells (Fig. 5A ) and increased activation of Src by cyt-PTPε in the cells (Fig. 5D) . Importantly, the last results show that PTPε is inhibited by its interaction with tubulin not only in vitro but also in intact cells. We note that nocodazole-induced mitotic arrest of cells increased activity of the related RPTP␣ and increased its ability to activate Src (50) in a manner suggested to be linked with phosphorylation of the juxtamembrane residues S180 and S204 of RPTP␣ (48) . Although the effect of nocodazole on RPTP␣ activity is consistent with results presented in the present study, the experimental systems are not identical. In particular, nocodazole-induced mitotic arrest requires significantly longer treatment of cells with nocodazole (10 h [50] versus 45 min in the present study); furthermore, S180 is not conserved in PTPε, and replacement of the residue in PTPε analogous to S204 with an aspartic acid residue did not affect PTPε activity towards Src (4). It remains, therefore, to be determined whether the molecular mechanisms that regulate phosphatase activity are the same in both cases.
Binding of cyt-PTPε to tubulin is affected by physiological signals in a reversible manner and with rapid kinetics typical of signaling processes. Activation of the EGFR results in phosphorylation of cyt-PTPε specifically at its C-terminal Y638, an event that is required for increased binding of the phosphatase to tubulin in this context. Increased binding and phosphorylation of cyt-PTPε occur rapidly after receptor activation and follow closely the time course of receptor autophosphorylation. Since association with microtubules reduces activity of cyt-PTPε in cells (Fig. 5A) , this result makes it tempting to speculate that increased binding of cyt-PTPε to microtubules during the initial stages of EGFR activation reduces phosphatase activity and removes it from the immediate vicinity of the receptor. The dependence on specific phosphorylation of cyt-PTPε downstream of the EGFR should ensure that cyt-PTPε binds microtubules in concert with a true physiological signal and in a manner most likely limited to the vicinity of the activated receptor. At later time points, phosphorylation of cyt-PTPε and its binding to microtubules are reduced, restoring the conditions that existed prior to EGFR stimulation. This latter process is most likely driven by the normal down-regulation of EGFR signaling and by auto-and trans-dephosphorylation of cyt-PTPε (4). We note that the receptor type of PTPε, RPTPε, binds microtubules constitutively in mammary tumor cells induced in mice by Neu. RPTPε is constitutively phosphorylated at Y695 (Y638 of cyt-PTPε) in these cells (4) , providing another correlation between phosphorylation of PTPε at its Cterminal tyrosine downstream of a (constitutively active) growth factor receptor and increased binding of microtubules. RPTPε activates Src and supports the transformed phenotype of these tumor cells (16) , suggesting that the fraction of RPTPε molecules that bind microtubules in this system may perform a distinct role. The precise mechanism by which phosphorylation of PTPε promotes its binding to microtubules is unknown at present. It is possible that phosphorylation promotes association of cyt-PTPε with additional proteins that are needed to stabilize the interaction with microtubules, in agreement with promotion of this interaction by MAPs. Further studies are required to address this issue.
In summary, this study suggests that association of PTPε with microtubules is a novel mechanism for regulation of PTPε activity that is regulated by physiological signals in a dynamic and reversible manner. We note that our data do not rule out other possible roles for the tubulin-PTPε association, such as regulating microtubule dynamics or providing access for PTPε to other molecules that also bind microtubules. The data suggest that the effect of microtubules is not limited to PTPε but may affect other tyrosine phosphatases, thereby providing an additional mechanism for physiological regulation of phosphatase activity.
